CpG motifs in bacterial DNA trigger direct B-cell activation
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Unmethylated CpG dinucleotides are more frequent in the genomes of bacteria and viruses than of vertebrates. We report here that bacterial DNA and synthetic oligodeoxynucleotides containing unmethylated CpG dinucleotides induce murine B cells to proliferate and secrete immunoglobulin in vitro and in vivo. This activation is enhanced by simultaneous signals delivered through the antigen receptor. Optimal B-cell activation requires a DNA motif in which an unmethylated CpG dinucleotide is flanked by two 5' purines and two 3' pyrimidines. Oligodeoxynucleotides containing this CpG motif induce more than 95% of all spleen B cells to enter the cell cycle. These data suggest a possible evolutionary link between immune defence based on the recognition of microbial DNA and the phenomenon of 'CpG suppression' in vertebrates. The potent immune activation by CpG oligonucleotides has implications for the design and interpretation of studies using 'antisense' oligonucleotides and points to possible new applications as adjuvants.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Unmethylated CpG motifs in bacterial DNA are potent triggers of inflammation (Klinman et al., 1997; Krieg et al., 1995).”
From Cytoplasmic DNA: sources, sensing, and role in aging and disease (2021) · cites this paper as Krieg et al., 1995
In the citing paper
“CpG DNA is a potent stimulator of TLR9 (12).”
From Repeated TLR9 stimulation results in macrophage activation syndrome–like disease in mice (2011) · cites this paper as [12]
Citations
Cites
Antisense Oligonucleotides as Therapeutic Agents—Is the Bullet Really Magical?
Stein, C. A., & Cheng, Y.-C. (1993) · Science · doi:10.1126/science.8351515 · Cited by 1,303
Gene inhibition using antisense oligodeoxynucleotides
Wagner, R. W. (1994) · Nature · doi:10.1038/372333a0 · Cited by 736
CpG islands as gene markers in the vertebrate nucleus
Bird, A. P. (1987) · Trends in Genetics · doi:10.1016/0168-9525(87)90294-0 · Cited by 678
Current concepts in antisense drug design
Milligan, J. F., Matteucci, M. D., & Martin, J. C. (1993) · Journal of Medicinal Chemistry · doi:10.1021/jm00066a001 · Cited by 566
Richardson, B., Scheinbart, L., Strahler, J., Gross, L., Hanash, S., & Johnson, M. (1990) · Arthritis & Rheumatism · doi:10.1002/art.1780331109 · Cited by 562
Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice.
Agrawal, S., Temsamani, J., & Tang, J. Y. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.17.7595 · Cited by 561
Therapeutic Applications of Oligonucleotides
Crooke, S. T. (1992) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pa.32.040192.001553 · Cited by 446
Stimulation of in vitro murine lymphocyte proliferation by bacterial DNA
Messina, J. P., Gilkeson, G. S., & Pisetsky, D. S. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.147.6.1759 · Cited by 371
Lymphocyte stimulation: a rapid multiparameter analysis.
Darzynkiewicz, Z., Traganos, F., Sharpless, T., & Melamed, M. R. (1976) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.73.8.2881 · Cited by 347
Frequency of B lymphocytes responsive to anti-immunoglobulin.
Defranco, A. L., Raveche, E. S., Asofsky, R., & Paul, W. E. (1982) · The Journal of experimental medicine · doi:10.1084/jem.155.5.1523 · Cited by 293
Research works printed but not linked: 1
- Krapf, F., Herrmann, M., Leitmann, W. & Kalden, J. R. Clin. exp. immun. 75, 336–342 (1989).
Cited by
Items 201–300 of 1,013
Halperin, S. A., Van Nest, G., Smith, B., Abtahi, S., Whiley, H., & Eiden, J. J. (2003) · Vaccine · doi:10.1016/s0264-410x(03)00045-8 · Cited by 259
Macfarlane, D. E., & Manzel, L. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.3.1122 · Cited by 261
Cho, H. J., Takabayashi, K., Cheng, P.-M., Nguyen, M.-D., Corr, M., Tuck, S., & Raz, E. (2000) · Nature Biotechnology · doi:10.1038/75365 · Cited by 258
Yasuda, K., Yu, P., Kirschning, C. J., Schlatter, B., Schmitz, F., Heit, A., Bauer, S., Hochrein, H., & Wagner, H. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.10.6129 · Cited by 255
Freytag, L. C., & Clements, J. D. (2005) · Vaccine · doi:10.1016/j.vaccine.2004.11.010 · Cited by 252
Herzner, A.-M., Hagmann, C. A., Goldeck, M., Wolter, S., Kübler, K., Wittmann, S., Gramberg, T., Andreeva, L., Hopfner, K.-P., Mertens, C., et al. (2015) · Nature Immunology · doi:10.1038/ni.3267 · Cited by 256
Shirota, Y., Shirota, H., & Klinman, D. M. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1101304 · Cited by 257
Self-citationCpG motifs in bacterial DNA cause inflammation in the lower respiratory tract.
Schwartz, D. A., Quinn, T. J., Thorne, P. S., Sayeed, S., Yi, A. K., & Krieg, A. M. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119523 · Cited by 254
Self-citationDivergent Therapeutic and Immunologic Effects of Oligodeoxynucleotides with Distinct CpG Motifs
Ballas, Z. K., Krieg, A. M., Warren, T., Rasmussen, W., Davis, H. L., Waldschmidt, M., & Weiner, G. J. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.9.4878 · Cited by 252
Self-citationStein, C. A. (1995) · Nature Medicine · doi:10.1038/nm1195-1119 · Cited by 255
Immunostimulatory DNA: Sequence‐dependent production of potentially harmful or useful cytokines
Lipford, G. B., Sparwasser, T., Bauer, M., Zimmermann, S., Koch, E., Heeg, K., & Wagner, H. (1997) · European Journal of Immunology · doi:10.1002/eji.1830271242 · Cited by 251
Recognition of CpG DNA is mediated by signaling pathways dependent on the adaptor protein MyD88
Schnare, M., Holt†, A. C., Takeda, K., Akira, S., & Medzhitov, R. (2000) · Current Biology · doi:10.1016/s0960-9822(00)00700-4 · Cited by 252
The role of CpG dinucleotides in DNA vaccines
Krieg, A. M., Yi, A.-K., Schorr, J., & Davis, H. L. (1998) · Trends in Microbiology · doi:10.1016/s0966-842x(97)01145-1 · Cited by 248
Self-citationSafety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine
Cooper, C. L., Davis, H. L., Morris, M. L., Efler, S. M., Krieg, A. M., Li, Y., Laframboise, C., Al Adhami, M. J., Khaliq, Y., Seguin, I., et al. (2004) · Vaccine · doi:10.1016/j.vaccine.2004.01.058 · Cited by 248
Self-citationRecent Advances in Vaccine Adjuvants
Singh, M., & O'Hagan, D. T. (2002) · Pharmaceutical Research · doi:10.1023/a:1016104910582 · Cited by 245
Summerton, J. (2007) · Current Topics in Medicinal Chemistry · doi:10.2174/156802607780487740 · Cited by 238
Antigen depot is not required for alum adjuvanticity
Hutchison, S., Benson, R. A., Gibson, V. B., Pollock, A. H., Garside, P., & Brewer, J. M. (2012) · The FASEB Journal · doi:10.1096/fj.11-184556 · Cited by 244
Repetitive Elements in Mammalian Telomeres Suppress Bacterial DNA-Induced Immune Activation
Gursel, I., Gursel, M., Yamada, H., Ishii, K. J., Takeshita, F., & Klinman, D. M. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.3.1393 · Cited by 241
Self-citationNau, R., & Eiffert, H. (2002) · Clinical Microbiology Reviews · doi:10.1128/cmr.15.1.95-110.2002 · Cited by 240
Sweeten PAMPs: Role of sugar complexed PAMPs in innate immunity and vaccine biology
Mahla, R. S. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00248 · Cited by 239
Yi, A.-K., Chang, M., Peckham, D. W., Krieg, A. M., & Ashman, R. F. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.12.5898 · Cited by 241
Self-citationVariable expression of Toll-like receptor in murine innate and adaptive immune cell lines
Applequist, S. E. (2002) · International Immunology · doi:10.1093/intimm/dxf069 · Cited by 238
Tousignant, J. D., Gates, A. L., Ingram, L. A., Johnson, C. L., Nietupski, J. B., Cheng, S. H., Eastman, S. J., & Scheule, R. K. (2000) · Human Gene Therapy · doi:10.1089/10430340050207984 · Cited by 236
Antisense oligonucleotide-based therapeutics for cancer
Dean, N. M., & Bennett, C. F. (2003) · Oncogene · doi:10.1038/sj.onc.1207231 · Cited by 234
Mucosal immunity and tolerance: relevance to vaccine development
Czerkinsky, C., Anjueie, F., McGhee, J. R., Geoige‐Chundy, A., Holmgren, J., Kieny, M., Fujiyashi, K., Mestecky, J. F., Pierrefite‐Carle, V., Rusk, C., et al. (1999) · Immunological Reviews · doi:10.1111/j.1600-065x.1999.tb01339.x · Cited by 238
Tan, Y., Li, S., Pitt, B. R., & Huang, L. (1999) · Human Gene Therapy · doi:10.1089/10430349950017149 · Cited by 237
McMahon, J., Signori, E., Wells, K., Fazio, V., & Wells, D. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301522 · Cited by 236
Rankin, R., Pontarollo, R., Ioannou, X., Krieg, A. M., Hecker, R., Babiuk, L. A., & van Drunen Littel-van den Hurk, S. (2001) · Antisense and Nucleic Acid Drug Development · doi:10.1089/108729001753231713 · Cited by 235
Self-citationGenomic DNA Released by Dying Cells Induces the Maturation of APCs
Ishii, K. J., Suzuki, K., Coban, C., Takeshita, F., Itoh, Y., Matoba, H., Kohn, L. D., & Klinman, D. M. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.5.2602 · Cited by 237
Self-citationYung, R., Powers, D., Johnson, K., Amento, E., Carr, D., Laing, T., Yang, J., Chang, S., Hemati, N., & Richardson, B. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118743 · Cited by 238
LENERT, P., BRUMMEL, R., Field, E. H., & ASHMAN, R. F. (2005) · Journal of Clinical Immunology · doi:10.1007/s10875-005-0355-6 · Cited by 234
Biodegradable Particles as Vaccine Delivery Systems: Size Matters
Joshi, V. B., Geary, S. M., & Salem, A. K. (2013) · The AAPS Journal · doi:10.1208/s12248-012-9418-6 · Cited by 233
mRNA as gene therapeutic: How to control protein expression
Tavernier, G., Andries, O., Demeester, J., Sanders, N. N., De Smedt, S. C., & Rejman, J. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.10.020 · Cited by 232
Kim, B., Tang, Q., Biswas, P. S., Xu, J., Schiffelers, R. M., Xie, F. Y., Ansari, A. M., Scaria, P. V., Woodle, M. C., Lu, P., et al. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63267-1 · Cited by 234
Silencing of episomal transgene expression by plasmid bacterial DNA elements in vivo
Chen, Z. Y., He, C. Y., Meuse, L., & Kay, M. A. (2004) · Gene Therapy · doi:10.1038/sj.gt.3302231 · Cited by 231
Phage display as a promising approach for vaccine development
Aghebati-Maleki, L., Bakhshinejad, B., Baradaran, B., Motallebnezhad, M., Aghebati-Maleki, A., Nickho, H., Yousefi, M., & Majidi, J. (2016) · Journal of Biomedical Science · doi:10.1186/s12929-016-0285-9 · Cited by 233
Generation and maintenance of immunological memory
Gourley, T. S., Wherry, E. J., Masopust, D., & Ahmed, R. (2004) · Seminars in Immunology · doi:10.1016/j.smim.2004.08.013 · Cited by 231
Agrawal, S., Jiang, Z., Zhao, Q., Shaw, D., Cai, Q., Roskey, A., Channavajjala, L., Saxinger, C., & Zhang, R. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.6.2620 · Cited by 226
Pawar, R. D., Ramanjaneyulu, A., Kulkarni, O. P., Lech, M., Segerer, S., & Anders, H.-J. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006101162 · Cited by 227
Edwards, A. D., Manickasingham, S. P., Spörri, R., Diebold, S. S., Schulz, O., Sher, A., Kaisho, T., Akira, S., & Reis e Sousa, C. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.7.3652 · Cited by 226
Li, S., Wu, S.-P., Whitmore, M., Loeffert, E. J., Wang, L., Watkins, S. C., Pitt, B. R., & Huang, L. (1999) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.1999.276.5.l796 · Cited by 225
Dong, Q., Louahed, J., Vink, A., Sullivan, C. D., Messler, C. J., Zhou, Y., Haczku, A., Huaux, F., Arras, M., Holroyd, K. J., et al. (1999) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(199907)29:07<2130::aid-immu2130>3.0.co;2-s · Cited by 128
Innate immune recognition of, and regulation by, DNA
ISHII, K., & AKIRA, S. (2006) · Trends in Immunology · doi:10.1016/j.it.2006.09.002 · Cited by 224
Walker, P. S., Scharton-Kersten, T., Krieg, A. M., Love-Homan, L., Rowton, E. D., Udey, M. C., & Vogel, J. C. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.12.6970 · Cited by 222
Self-citationCpG-Depleted Plasmid DNA Vectors with Enhanced Safety and Long-Term Gene Expression in Vivo
Yew, N. S., Zhao, H., Przybylska, M., Wu, I.-H., Tousignant, J. D., Scheule, R. K., & Cheng, S. H. (2002) · Molecular Therapy · doi:10.1006/mthe.2002.0598 · Cited by 223
Yew, N. S., Zhao, H., Wu, I.-H., Song, A., Tousignant, J. D., Przybylska, M., & Cheng, S. H. (2000) · Molecular Therapy · doi:10.1006/mthe.2000.0036 · Cited by 221
Gallichan, W. S., Woolstencroft, R. N., Guarasci, T., McCluskie, M. J., Davis, H. L., & Rosenthal, K. L. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.5.3451 · Cited by 220
Biological features of genetic immunization
Barry, M. (1997) · Vaccine · doi:10.1016/s0264-410x(96)00265-4 · Cited by 221
Delivery of 5-Aza-2′-Deoxycytidine to Cells Using Oligodeoxynucleotides
Yoo, C. B., Jeong, S., Egger, G., Liang, G., Phiasivongsa, P., Tang, C., Redkar, S., & Jones, P. A. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0251 · Cited by 219
Aptamer Therapeutics in Cancer: Current and Future
Morita, Y., Leslie, M., Kameyama, H., Volk, D., & Tanaka, T. (2018) · Cancers · doi:10.3390/cancers10030080 · Cited by 217
Kawarada, Y., Ganss, R., Garbi, N., Sacher, T., Arnold, B., & Hämmerling, G. J. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.9.5247 · Cited by 220
Master sensors of pathogenic RNA – RIG-I like receptors
Schlee, M. (2013) · Immunobiology · doi:10.1016/j.imbio.2013.06.007 · Cited by 217
Microparticles as vaccine adjuvants and delivery systems
O’Hagan, D. T., & Singh, M. (2003) · Expert Review of Vaccines · doi:10.1586/14760584.2.2.269 · Cited by 214
Intratumoral Immunization: A New Paradigm for Cancer Therapy
Marabelle, A., Kohrt, H., Caux, C., & Levy, R. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2116 · Cited by 214
Liljeqvist, S., & Ståhl, S. (1999) · Journal of Biotechnology · doi:10.1016/s0168-1656(99)00107-8 · Cited by 214
Cutting Edge: Rapid Induction of Mitogen-Activated Protein Kinases by Immune Stimulatory CpG DNA
Yi, A.-K., & Krieg, A. M. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.9.4493 · Cited by 175
Self-citationHeer, A. K., Shamshiev, A., Donda, A., Uematsu, S., Akira, S., Kopf, M., & Marsland, B. J. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.4.2182 · Cited by 209
DNA Sensing in the Innate Immune Response
Briard, B., Place, D. E., & Kanneganti, T.-D. (2020) · Physiology · doi:10.1152/physiol.00022.2019 · Cited by 211
A combination of poloxamers increases gene expression of plasmid DNA in skeletal muscle
Lemieux, P., Guérin, N., Paradis, G., Proulx, R., Chistyakova, L., Kabanov, A., & Alakhov, V (2000) · Gene Therapy · doi:10.1038/sj.gt.3301189 · Cited by 213
Gürsel, M., Verthelyi, D., Gürsel, I., Ishii, K. J., & Klinman, D. M. (2002) · Journal of Leukocyte Biology · doi:10.1189/jlb.71.5.813 · Cited by 214
Self-citationWiseman, J. W., Goddard, C. A., McLelland, D., & Colledge, W. H. (2003) · Gene Therapy · doi:10.1038/sj.gt.3302050 · Cited by 211
“Smart” delivery of antisense oligonucleotides by anionic pH-sensitive liposomes
Fattal, E. (2004) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2003.10.037 · Cited by 211
Interactions between bacterial CpG-DNA and TLR9 bridge innate and adaptive immunity
Wagner, H. (2002) · Current Opinion in Microbiology · doi:10.1016/s1369-5274(02)00287-4 · Cited by 211
Decker, T., Schneller, F., Sparwasser, T., Tretter, T., Lipford, G. B., Wagner, H., & Peschel, C. (2000) · Blood · doi:10.1182/blood.v95.3.999.003k10_999_1006 · Cited by 210
Viral recognition by Toll-like receptors
Barton, G. M. (2007) · Seminars in Immunology · doi:10.1016/j.smim.2007.01.003 · Cited by 210
Strategies for enhancing the immunostimulatory effects of CpG oligodeoxynucleotides
Mutwiri, G. K., Nichani, A. K., Babiuk, S., & Babiuk, L. A. (2004) · Journal of Controlled Release · doi:10.1016/j.jconrel.2004.02.022 · Cited by 208
Recent advances in veterinary vaccine adjuvants
Singh, M., & O'Hagan, D. T. (2003) · International Journal for Parasitology · doi:10.1016/s0020-7519(03)00053-5 · Cited by 207
Activation of toll‐like receptor‐9 induces progression of renal disease in MRL‐Fas(lpr) mice
Anders, H., Vielhauer, V., Eis, V., Linde, Y., Kretzler, M., Perez de Lema, G., Strutz, F., Bauer, S., Rutz, M., Wagner, H., et al. (2004) · The FASEB Journal · doi:10.1096/fj.03-0646fje · Cited by 209
Activation of Toll-Like Receptor 9 by DNA from Different Bacterial Species
Dalpke, A., Frank, J., Peter, M., & Heeg, K. (2006) · Infection and Immunity · doi:10.1128/iai.74.2.940-946.2006 · Cited by 209
Han, S.-S., Chung, S.-T., Robertson, D. A., Ranjan, D., & Bondada, S. (1999) · Clinical Immunology · doi:10.1006/clim.1999.4769 · Cited by 207
CpG DNA and LPS induce distinct patterns of activation in human monocytes
Hartmann, G., & Krieg, A. M. (1999) · Gene Therapy · doi:10.1038/sj.gt.3300880 · Cited by 208
Self-citationHornung, V., Schlender, J., Guenthner-Biller, M., Rothenfusser, S., Endres, S., Conzelmann, K.-K., & Hartmann, G. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.10.5935 · Cited by 205
Exploration of the nanomedicine-design space with high-throughput screening and machine learning
Yamankurt, G., Berns, E. J., Xue, A., Lee, A., Bagheri, N., Mrksich, M., & Mirkin, C. A. (2019) · Nature Biomedical Engineering · doi:10.1038/s41551-019-0351-1 · Cited by 199
Simons, F. E. R., Shikishima, Y., Van Nest, G., Eiden, J. J., & HayGlass, K. T. (2004) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2004.03.003 · Cited by 204
Wooldridge, J. E., Ballas, Z., Krieg, A. M., & Weiner, G. J. (1997) · Blood · doi:10.1182/blood.v89.8.2994 · Cited by 203
Self-citationYew, N. S., Wang, K. X., Przybylska, M., Bagley, R. G., Stedman, M., Marshall, J., Scheule, R. K., & Cheng, S. H. (1999) · Human Gene Therapy · doi:10.1089/10430349950019011 · Cited by 205
T granules in human platelets function in TLR9 organization and signaling
Thon, J. N., Peters, C. G., Machlus, K. R., Aslam, R., Rowley, J., Macleod, H., Devine, M. T., Fuchs, T. A., Weyrich, A. S., Semple, J. W., et al. (2012) · Journal of Cell Biology · doi:10.1083/jcb.201111136 · Cited by 203
Biomaterials for vaccine-based cancer immunotherapy
Zhang, R., Billingsley, M. M., & Mitchell, M. J. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.10.008 · Cited by 200
Antisense oligonucleotides: A primer
Scoles, D. R., Minikel, E. V., & Pulst, S. M. (2019) · Neurology Genetics · doi:10.1212/nxg.0000000000000323 · Cited by 200
The commensal skin microbiota triggers type I IFN–dependent innate repair responses in injured skin
Di Domizio, J., Belkhodja, C., Chenuet, P., Fries, A., Murray, T., Mondéjar, P. M., Demaria, O., Conrad, C., Homey, B., Werner, S., et al. (2020) · Nature Immunology · doi:10.1038/s41590-020-0721-6 · Cited by 207
Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides
Krieg, A. M. (2004) · Current Oncology Reports · doi:10.1007/s11912-004-0019-0 · Cited by 200
Self-citationStructure-dependent immunostimulatory effect of CpG oligodeoxynucleotides and their delivery system
Hanagata, N. (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s30197 · Cited by 197
Brandau, D. T., Jones, L. S., Wiethoff, C. M., Rexroad, J., & Middaugh, C. R. (2003) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.10296 · Cited by 199
Nanoparticulate systems for the delivery of antisense oligonucleotides
Lambert, G., Fattal, E., & Couvreur, P. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00116-2 · Cited by 201
CpG Oligodeoxynucleotides as Vaccine Adjuvants in Primates
Verthelyi, D., Kenney, R. T., Seder, R. A., Gam, A. A., Friedag, B., & Klinman, D. M. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.4.1659 · Cited by 199
Self-citationScheel, B., Teufel, R., Probst, J., Carralot, J., Geginat, J., Radsak, M., Jarrossay, D., Wagner, H., Jung, G., Rammensee, H., et al. (2005) · European Journal of Immunology · doi:10.1002/eji.200425656 · Cited by 199
Hajizadeh, S., DeGroot, J., TeKoppele, J. M., Tarkowski, A., & Collins, L. V. (2003) · Arthritis Res Ther · doi:10.1186/ar787 · Cited by 196
“DNA containing unmethylated CpG motifs has been reported to have immunostimulatory properties [14–16], and the presence of this type of DNA in joints has been linked with arthritides in mice [3] and humans [17].”
Spies, B., Hochrein, H., Vabulas, M., Huster, K., Busch, D. H., Schmitz, F., Heit, A., & Wagner, H. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.11.5908 · Cited by 199
Trial Watch: Experimental Toll-like receptor agonists for cancer therapy
Galluzzi, L., Vacchelli, E., Eggermont, A., Fridman, W. H., Galon, J., Sautès-Fridman, C., Tartour, E., Zitvogel, L., & Kroemer, G. (2012) · OncoImmunology · doi:10.4161/onci.20696 · Cited by 195
Yi, A.-K., Yoon, J.-G., Yeo, S.-J., Hong, S.-C., English, B. K., & Krieg, A. M. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.9.4711 · Cited by 196
Self-citationKyburz, D., Rethage, J., Seibl, R., Lauener, R., Gay, R. E., Carson, D. A., & Gay, S. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10848 · Cited by 196
Heckelsmiller, K., Rall, K., Beck, S., Schlamp, A., Seiderer, J., Jahrsdörfer, B., Krug, A., Rothenfusser, S., Endres, S., & Hartmann, G. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.7.3892 · Cited by 194
Current prospects for mRNA gene delivery
Yamamoto, A., Kormann, M., Rosenecker, J., & Rudolph, C. (2009) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2008.09.016 · Cited by 190
Tamura, S.-I., Tanimoto, T., & Kurata, T. (2005) · Japanese Journal of Infectious Diseases · doi:10.7883/yoken.jjid.2005.195 · Cited by 195
In vivo studies with antisense oligonucleotides
Akhtar, S., & Agrawal, S. (1997) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(96)01002-4 · Cited by 195
Neuronal injury mediated via stimulation of microglial toll-like receptor-9 (TLR9)
Iliev, A. I., Stringaris, A. K., Nau, R., & Neumann, H. (2004) · The FASEB Journal · doi:10.1096/fj.03-0670fje · Cited by 192
Wack, A., Baudner, B. C., Hilbert, A. K., Manini, I., Nuti, S., Tavarini, S., Scheffczik, H., Ugozzoli, M., Singh, M., Kazzaz, J., et al. (2008) · Vaccine · doi:10.1016/j.vaccine.2007.11.054 · Cited by 195
Silencing or Stimulation? siRNA Delivery and the Immune System
Whitehead, K. A., Dahlman, J. E., Langer, R. S., & Anderson, D. G. (2011) · Annual Review of Chemical and Biomolecular Engineering · doi:10.1146/annurev-chembioeng-061010-114133 · Cited by 191
Jelinek, I., Leonard, J. N., Price, G. E., Brown, K. N., Meyer-Manlapat, A., Goldsmith, P. K., Wang, Y., Venzon, D., Epstein, S. L., & Segal, D. M. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1002845 · Cited by 190
Toll-like receptor 9 mediates CpG-DNA signaling
Chuang, T.-H., Lee, J., Kline, L., Mathison, J. C., & Ulevitch, R. J. (2002) · Journal of Leukocyte Biology · doi:10.1189/jlb.71.3.538 · Cited by 192
Metadata
- Authors
- Krieg, A. M., Yi, A.-K., Matson, S., Waldschmidt, T. J., Bishop, G. A., Teasdale, R., Koretzky, G. A., & Klinman, D. M.
- Affiliations
- University of Iowa (US)
- Center for Biologics Evaluation and Research (US)
- ORCID
- Venue
- Nature
- Published
- 1995-04
- Volume
- 374
- Issue
- 6522
- Pages
- 546-549
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2047366876
- Cited by
- 3,508
- References
- 28
- Citations by year
- 2026: 24 · 2025: 36 · 2024: 47 · 2023: 43 · 2022: 58 · 2021: 58 · 2020: 84 · 2019: 84 · 2018: 58 · 2017: 69 · 2016: 76 · 2015: 89 · 2014: 83 · 2013: 102 · 2012: 104
- FWCI
- 36.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- CpG motifs, bacterial DNA, B cell activation, B cell proliferation, immunoglobulin secretion, antigen receptor signaling, CpG oligodeoxynucleotides, CpG suppression, antisense oligonucleotides, adjuvants
- MeSH terms
- Animals, B-Lymphocytes, Base Sequence, Cell Line, DNA, Bacterial, Escherichia coli, Lymphocyte Activation, Methylation, Mice, Inbred DBA, Molecular Sequence Data, Oligodeoxyribonucleotides, T-Lymphocytes, Dinucleoside Phosphates, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.